Clinical and Demographic Characteristics and Two-Year Efficacy and Safety Data of 508 Multiple Sclerosis Patients with Fingolimod Treatment

Basit Öğe Kaydı
dc.authoridTurkoglu, Recai/0000-0001-9724-851X
dc.authoridAydin Turkoglu, Sule/0000-0001-8616-832X
dc.authoridKOTAN, DILCAN/0000-0002-3101-4742
dc.authoridYoldas, Tahir Kurtulus/0000-0003-4950-9142
dc.contributor.authorTerzi, Murat
dc.contributor.authorHelvaci, Elif Merve
dc.contributor.authorSen, Sedat
dc.contributor.authorBoz, Cavit
dc.contributor.authorCilingir, Vedat
dc.contributor.authorAkcali, Aylin
dc.contributor.authorBeckmann, Yesim
dc.date.accessioned2025-01-27T20:49:30Z
dc.date.available2025-01-27T20:49:30Z
dc.date.issued2023
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractIntroduction: Fingolimod is the first oral immunomodulatory treatment used as secondary care therapy in the treatment of multiple sclerosis for the last 10 years. The objective of our study is to reveal the experiences of the first generic fingolimod active ingredient treatment in different centers across Turkey. Method: The first generic fingolimod efficacy and safety data of patients followed-up in 29 different clinical multiple sclerosis units in Turkey were analyzed retrospectively. Data regarding efficacy and safety of the patients were transferred to the data system both before the treatment and on the 6th, 12th and 24th month following the treatment. The data were analyzed using the IBM SPSS 20.00. P value of <0.05 was considered to be statistically significant. Results: A total of 508 multiple sclerosis patients, 331 of whom were women, were included in the study. Upon comparing the Expanded Disability Status values before and after the treatment, a significant decrease was observed, especially at month 6 and thereafter. Since bradycardia occurred in 11 of the patients (2.3%), the first dose had to be longer than 6 hours. During the observation of the first dose, no issues that could prevent the use of the drug occured. Side effects were seen in 49 (10.3%) patients during the course of fingolimod treatment. Respectively, the most frequent side effects were bradycardia, hypotension, headache, dizziness and tachycardia. Conclusion: The observed results regarding efficacy and safety were similar to clinical trial data in the literature and real life data in terms of the first equivalent with fingolimod active ingredient.
dc.description.sponsorshipSANOVEL
dc.description.sponsorshipThanks to SANOVEL for funding the publication process.
dc.identifier.doi10.29399/npa.28081
dc.identifier.endpage27
dc.identifier.issn1300-0667
dc.identifier.issn1309-4866
dc.identifier.issue1
dc.identifier.pmid36911568
dc.identifier.startpage23
dc.identifier.trdizinid1169769
dc.identifier.urihttps://doi.org/10.29399/npa.28081
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1169769
dc.identifier.urihttps://hdl.handle.net/20.500.12428/25192
dc.identifier.volume60
dc.identifier.wosWOS:001190959500002
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTurkish Neuropsychiatry Assoc-Turk Noropsikiyatri Dernegi
dc.relation.ispartofNoropsikiyatri Arsivi-Archives of Neuropsychiatry
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectEfficacy
dc.subjectfingolimod
dc.subjectmultiple sclerosis
dc.subjectsafety
dc.titleClinical and Demographic Characteristics and Two-Year Efficacy and Safety Data of 508 Multiple Sclerosis Patients with Fingolimod Treatment
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu